Home › Liver Cancer (Hepatocellular Carcinoma) › NCT05953961

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

Randomized Study of Therapshere 90-Yittrium Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* HCC diagnosis according to the Liver Imaging - Reporting Data System (LI-RADS) Criteria as defined in the American Association for the Study of Liver Diseases 2018 HCC practice guidelines
* Eastern Cooperative Oncology Group score 0 - 1
* Child-Pugh A - B
* Bilirubin \< 2.5 mg/dL
* Creatinine \< 2.0 mg/dL
* No prior liver-directed therapy or systemic therapy for HCC
* Solitary, unresectable HCC ≤ 3cm
* Albumin level \< 3.4 g/dL at HCC diagnosis
* Tumor anatomical location and angiosome amendable to MWA and 90Y

Exclusion Criteria:

* Pregnant women
* Concurrent malignancy

About the study

This clinical trial will compare 1-year outcomes in patients with hypoalbuminemia and a new diagnosis of small, early-stage hepatocellular carcinoma (HCC) who are candidates for both 90-Yittrium Therasphere transarterial radioembolization (90Y) and microwave ablation (MWA). The study will determine whether treatment with 90Y lowers the risk of disease progression within the first year after diagnosis. Participants will be randomized to receive either first cycle 90Y or MWA and then proceed with standard of care.

What is being tested

• Therasphere 90Y (device)
• Microwave Ablation (device)

Sponsor: Ochsner Health System · Participants: 50 · Started: Aug 8, 2023

Contact the study team

• Ken Bode · Phone: 5048421936
• Amy Riehm · Phone: 5047039065

Official record on ClinicalTrials.gov — NCT05953961

Locations in the U.S.

Conditions

• Liver Cancer (Hepatocellular Carcinoma)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.